Guideline

Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection

Linda-Gail Bekker, Kevin Rebe, Francois Venter, Gary Maartens, Michelle Moorhouse, Francesca Conradie, Carole Wallis, Vivian Black, Beth Harley, Robyn Eakle
Southern African Journal of HIV Medicine | Vol 17, No 1 | a455 | DOI: https://doi.org/10.4102/sajhivmed.v17i1.455 | © 2016 Linda-Gail Bekker, Kevin Rebe, Francois Venter, Gary Maartens, Michelle Moorhouse, Francesca Conradie, Carole Wallis, Vivian Black, Beth Harley, Robyn Eakle | This work is licensed under CC Attribution 4.0
Submitted: 09 December 2015 | Published: 09 March 2016

About the author(s)

Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town, South Africa
Kevin Rebe, Anova Health Institute, Johannesburg, South Africa
Francois Venter, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Gary Maartens, Department of Medicine, University of Cape Town, South Africa
Michelle Moorhouse, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Francesca Conradie, Right to Care and Clinical HIV Research Unit, University of the Witwatersrand, South Africa
Carole Wallis, BARC, Johannesburg, South Africa; Lancet Laboratories, Johannesburg, South Africa
Vivian Black, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Beth Harley, City Health, City of Cape Town, South Africa
Robyn Eakle, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa


Share this article

Bookmark and Share

Abstract

The Southern African HIV Clinicians Society published its first set of oral pre-exposure prophylaxis (PrEP) guidelines in June 2012 for men who have sex with men (MSM) who are at risk of HIV infection. With the flurry of data that has been generated in PrEP clinical research since the first guideline, it became evident that there was a need to revise and expand the PrEP guidelines with new evidence of safety and efficacy of PrEP in several populations, including MSM, transgender persons, heterosexual men and women, HIV-serodiscordant couples and people who inject drugs. This need is particularly relevant following the World Health Organization (WHO) Consolidated Treatment Guidelines released in September 2015. These guidelines advise that PrEP is a highly effective, safe, biomedical option for HIV prevention that can be incorporated with other combination prevention strategies in Southern Africa, given the high prevalence of HIV in the region. PrEP should be tailored to populations at highest risk of HIV acquisition, whilst further data from studies in the region accrue to guide optimal deployment to realise the greatest impact regionally. PrEP may be used intermittently during periods of perceived HIV acquisition risk, rather than continually and lifelong, as is the case with antiretroviral treatment. Recognition and accurate measurement of potential risk in individuals and populations also warrants discussion, but are not extensively covered in these guidelines.

Keywords

Pre-exposure prophylaxis, clinical guideline

Metrics

Total abstract views: 3408
Total article views: 5216

 

Crossref Citations

1. Going global: the adoption of the World Health Organization’s enabling recommendation on oral pre-exposure prophylaxis for HIV
Ioannis Hodges-Mameletzis, Shona Dalal, Busisiwe Msimanga-Radebe, Michelle Rodolph, Rachel Baggaley
Sexual Health  vol: 15  issue: 6  first page: 489  year: 2018  
doi: 10.1071/SH18125